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Background. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) showed promising results in
selected patients. High morbidity restrains its wide application. The aim of this study was to report postoperative infectious
complications and investigate possible correlations with the preoperative nutritional status and other prognostic factors in
patients with peritoneal metastases treated with CRS and HIPEC. Methods. For the study, we reviewed the clinical records of all
patients with peritoneal metastases from different primary cancers treated with CRS and HIPEC in our Institution from
November 2000 to December 2017. Patients were divided according to their nutritional status (SGA) into groups A (well-
nourished) and B/C (mild or severely malnourished, respectively). Possible statistical correlations between risk factors and
postoperative complication rates have been investigated by univariate and multivariate analysis. Results. Two hundred patients
were selected and underwent CRS and HIPEC during the study period. Postoperative complications occurred in 44% of the
patients, 35.3% in SGA-A patients, and 53% in SGA-B/C patients. Cause of complications was infective in 42, noninfective in
37, and HIPEC related in 9 patients. Infectious complications occurred more frequently in SGA-B/C patients (32.6% vs. 9.8% of
SGA-A patients). The most frequent sites of infection were surgical site infections (SSI, 35.7%) and central line-associated
bloodstream infections (CLABSI, 26.2%). The most frequent isolated species was Candida (22.8%). ASA score, blood loss,
performance status, PCI, large bowel resection, postoperative serum albumin levels, and nutritional status correlated with higher
risk for postoperative infectious complications. Conclusions. Malnourished patients undergoing cytoreductive surgery and
hyperthermic intraperitoneal chemotherapy are more prone to postoperative infectious complications, and adequate
perioperative nutritional support should be considered, including immune-enhancing nutrition. Sequential monitoring of
common sites of infection, antifungal prevention of candidiasis, and careful patient selection should be implemented to reduce
the complication rate.
1. Introduction
Peritoneal metastases have long been considered a termi-
nal event in the natural history of many gynecological and
gastrointestinal (GI) cancers [1, 2], and the role of surgery
for patients with peritoneal surface malignancies has been
mostly palliation for tumor-related complications. Since the
introduction of cytoreductive surgery (CRS) and hyperther-
mic intraperitoneal chemotherapy (HIPEC) by Sugarbaker
in the early 90s [3], this treatment has expanded [4–13].
Despite promising results, these complex surgical proce-
dures carry high rates of postoperative complications and
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mortality, restraining the wide diffusion and feasibility of
these techniques [10, 11, 14–16].
A number of studies extensively report surgical and
HIPEC-related complications, but only few of them are
focused on postoperative infectious complications [2, 17–
20]. Moreover, nutritional status has been shown to have a
great impact on the immune system making patients with
impaired host immune response more susceptible to postop-
erative complications after gastrointestinal surgery [21–24]
including patients with ovarian and advanced colorectal can-
cer [25, 26], but the literature still lacks data about the impact
of nutritional status in the outcome of patients treated with
CRS and HIPEC for peritoneal carcinomatosis.
This is why we critically reviewed our Institution’s clini-
cal database of the patients who underwent CRS and HIPEC
for peritoneal metastases with the aim to investigate correla-
tions between possible prognostic factors and postoperative
infectious complications, focusing on nutritional status and
type of surgical procedures.
2. Materials and Methods
Patients with the diagnosis of peritoneal metastases from dif-
ferent primary cancers treated with cytoreductive surgery
and HIPEC were selected from a prospectively maintained
database in our Institution during a 17-year period from
November 2000 to December 2017. Inclusion criteria were
as follows: confirmed peritoneal metastases (histologically
and/or cytologically); age < 75 years; ECOG performance sta-
tus 0-2 [27]; adequate renal, liver, and bone marrow function;
resectable disease; and preoperative serum albumin level > 2
g/dl. All patients had a Body Mass Index (BMI) between
18.50 and 24.99 kg/m2, a range that defines the normal
weight population. We excluded from the study patients with
extra abdominal metastases and/or unresectable disease.
Nutritional status was evaluated as a risk factor for the
development of infectious complications and assessed by
providing each patient with a Subjective Global Assessment
(SGA) form [17]. Patients were classified into 3 groups:
well nourished (A), mildly moderately malnourished (B),
and severely malnourished (C). BMI, albumin level, and
cholesterol as well as triglycerides levels were considered to
assess the need for Total Parenteral Nutrition (TPN) sup-
port prior to surgery. Mildly (B) or severely (C) malnour-
ished patients received a minimum of 15 days of TPN and
vitamin supplementation.
All patients received antibiotic prophylaxis at induction
of anesthesia, with 2 g iv of ceftriaxone and 500mg iv of met-
ronidazole, repeated every 4 hours during the procedure and
24 hours after surgery.
Surgical procedures and HIPEC techniques have been
described in previous reports [3, 10]. The extent of peritoneal
disease and results of cytoreduction were classified using
the peritoneal cancer index (PCI) and completeness of
cytoreduction score (CC score) according to Sugarbaker
[28]. According to protocols in use in our Institution, the
drug used for HIPEC in 112 patients with gynecologic (ovar-
ian, endometrial, or breast) primary cancers was cisplatin
(75mg/m2), while in 79 patients with colorectal, gastric,
and pseudomyxoma peritonei, the drug was oxaliplatin
(460mg/m2 in 2 l/m2 of dextrose solution) plus intravenous
infusion of 5-FU (400mg/m2). The 9 cases of mesothelioma
underwent cisplatin and doxorubicin. Patients were sent to
the intensive care unit (ICU) in the immediate postoperative
period for at least 24 hours.
In all symptomatic patients with suspected infection
(fever > 38°C, dyspnea, dysuria, purulent surgical wound or
drain, increasing white cell count, and C-reactive protein-
CRP levels), blood cultures (a total of 3 samples, taken every
30min from both central venous lines (CVLs) and the
peripheral vein) and culture of the CVL tip and of biological
fluids including those from abdominal drainage and urine
cultures were performed. In case of sepsis from intra-
abdominal infection, an abdominal CT scan or ultrasound
was carried out to rule out and eventually to drain an intra-
abdominal fluid collection.
An empiric antimicrobial therapy with carbapenem
and teicoplanin was started until microbiologic results
were obtained. Antifungal therapy was associated when a
fungal infection was also suspected. Infected CVLs were
removed and replaced 48/72 hours after the beginning of
the therapy. Removal of the bladder catheter was manda-
tory after Candida contamination was proven. Once infec-
tion resolved, antimicrobial drug washout was performed for
at least 24 hours, followed by blood cultures and urinalysis.
No further investigations were carried out in the case of
symptom-free patients.
For each patient, we recorded demographic, clinical,
and pathological data: age, sex, comorbidities, nutritional
status assessment, type of primary tumor, ECOG perfor-
mance status, ASA score, time of cytoreduction (primary
or secondary), preoperative chemotherapy, type and length
of surgical procedures, PCI and CC score, blood loss, length
of ICU, and overall postoperative stay. Observed postoper-
ative adverse events have been recorded and divided as
infectious, surgical, or HIPEC-related and graded accord-
ing to the National Cancer Institute Common Terminol-
ogy Criteria for Adverse Events (CTCAE) 5.0 [29]. The
WHO chemotherapy toxicity scale was used to score cis-
platin toxicity [30]. In the case of infectious complications,
site of infection, type of sample collected, and etiology of
the infection were recorded.
Possible statistical correlations between risk factors and
postoperative complications rates have been investigated
by the mean of univariate analysis (log-rank test). Results
were matched by the mean of multivariate analysis (Cox
regression model) to identify independent variables influenc-
ing infections occurring, using the Statistical Package for
the Social Sciences for Windows (SPSS GmbH, Munich,
Germany). The 2-tailed p values below 0.05 were considered
statistically significant.
3. Results
During the considered study period, out of 421 patients who
underwent CRS+HIPEC for peritoneal surface malignancies
in our Institution, we selected 200 patients who fulfilled
the inclusion criteria. We excluded 77 patients for high
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BMI, 74 with an ECOG PS > 2, 41 for incomplete records,
and 29 because of age. Forty-three were male and 157 female.
Mean age was 61.3 years (range 32-75). Clinical characteris-
tics are reported in Table 1. One hundred and four patients
had previous chemotherapy regimens. Twenty-eight primary
advanced ovarian cancers underwent neoadjuvant treatment
with a platinum/paclitaxel-based regimen. Of the remaining
76 patients, 6 had systemic chemotherapy for breast cancer
several years before developing peritoneal metastases; 52
patients with peritoneal metastases from colorectal cancer
had previous (from 1 to 5 years before) FOLFOX/FOLFIRI
regimens. The remaining 18 patients (gastric and endome-
trial cancers) underwent neoadjuvant chemotherapy before
cytoreduction. All patients were admitted for surgery at least
two months after the end of the last chemotherapy regimen
and after having proven their immune competency by blood
tests. In order to achieve maximal cytoreduction, a total of
1360 surgical procedures were performed (Table 1).
An uneventful recovery was observed in 112 cases (56%).
Postoperative complications were observed in 88 patients
(44%). Cause of complications was infective-related in 42,
noninfective-related in 37, and HIPEC-related in 9 patients.
Mortality rate was 3.5%. Causes of death were sepsis and sub-
sequent multiorgan failure in 2 patients, complications of an
intra-abdominal abscess in 1 patient, and massive pulmonary
embolism despite a preoperative prophylactic low molecular-
weight heparin standard protocol in use in our Institution in
2 patients. The remaining 2 patients died of myocardial infarc-
tion (1) and of complications after bowel perforation (1).
Major complications (grades 3 to 4) occurred in 30
patients (15%), requiring interventional endoscopy or CT
scan/ultrasound-guided procedures, surgery, or readmission
in the ICU. Type and grade of the observed adverse events
are reported in Table 2. Etiology of infectious complications
was bacterial in 26, fungal in 6, and mixed bacterial/fungal
in 10 cases. Candida spp were the most frequent species iso-
lated, followed by E. coli, Klebsiella, and Staphylococcus epi-
dermidis. Sixty-two positive cultures were reported in the 42
patients with infectious complications. Etiology and site of
complication are reported in Table 3.
Complications were observed in 36 of 102 (35.3%) of the
patients in the SGA group A and in 52 of 98 (53%) of the
patients in SGA groups B/C (p < 0 05) while no statistical dif-
ference was observed for major complications in the 2 groups
(13.7% in group A vs. 23.4% in groups B/C, p: ns). The infec-
tious complication rate was higher in SGA groups B/C than
in SGA group A (9.8% vs. 32.6%, p < 0 01).
Infectious complications occurred in 30 cases in a single
site or organ, in 12 patients in multiple sites, 2 of which led
to septic shock and death. Infection was the only complication
in 14 patients and in 28 was associated with a surgical compli-
cation. A simultaneous infection occurred in 16 of the 58
patients (27.5%) with only one postoperative surgical compli-
cation and in 12 of the 16 patients (75%) in whom multiple
postoperative surgical complications occurred (p < 0 003).
Univariate analysis performed to correlate possible risk
factors and incidence of postoperative infective adverse
events showed that ASA score, performance status, SGA,
PCI, intraoperative blood loss, large bowel resection, and
postoperative serum albumin level were factors significantly
influencing postoperative infection rates (Table 4). Multivar-
iate analysis (Cox regression test) confirmed the ASA score,
intraoperative blood loss, large bowel resection, and SGA as
independent variables significantly linked with postoperative
infectious complications (Table 5).
4. Discussion
Mortality and morbidity rates after cytoreduction and
HIPEC vary greatly in the literature [2, 5, 31]. Possible reasons
Table 1: Clinical characteristics.
Variables Categories N %
ASA score
1 96 48
2 88 44
3 16 8
Performance
status (ECOG)
0 67 33.5
1-2 133 66.5
SGA score
A 102 51
B 78 39
C 20 10
Primary tumor
Ovarian 101 50.5
Colorectal 52 26
Gastric 16 8
Pseudomyxoma peritonei 11 5.5
Malignant mesothelioma 9 4.5
Breast 6 3
Endometrial 5 2.5
Peritoneal cancer
index (PCI)
Mean (range) 16.5 (6-29) —
Surgical
procedure
(tot. 1360)
Regional lymphadenectomy 198 —
Omentectomy 186 —
Implant excisions 164 —
Total/subtotal parietal 162 —
Peritonectomy —
Colorectal resections 138 —
Hysterectomy and
ovariectomy
118
Splenectomy 82 —
Cholecystectomy 74 —
Abdominal wall resections 50 —
Appendectomy 48 —
Small bowel resections 40 —
Pelvic mass excisions 26 —
Bladder resections 12 —
Liver resections 10 —
Gastric resections 4 —
Other 48 —
Completeness
of cytoreduction
(CC)
CC0 134 67
CC1 42 21
CC2/3 24 12
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could be that the definition and management themselves are
subjective, often depending on the surgeon’s attitude and
skills [5] and that different complication classifications are
currently used [11, 32]. It would be very important to stan-
dardize the adverse events reported in the literature, and the
use of the NCI-CTCAE could be helpful to report adverse
events in a homogeneous way to be easily compared.
Regarding type of operation, often cytoreductive sur-
gery procedures include multiple bowel resections in the
attempt to obtain a CC-0 score, and interestingly, our results
identify colorectal resections as a variable influencing the
postoperative infection rate. This should be carefully consid-
ered during planning of surgical strategy, avoiding large bowel
resections in favor of more conservative surgical choices to
reduce the risk of postoperative infectious adverse events.
Mortality (3.5%) and morbidity (44%) reported in our
series match with those reported in previous studies [6, 10,
11, 17, 32, 33]. Quenet et al. recently reported the results of
the PRODIGE-7 trial with a HIPEC-related 60-day major
morbidity (grades 3-5) of 24.1% [34]. We observed an
Table 2: Postoperative adverse events (as graded by CTCAE severity score v 5.0).
Adverse events N % Grade 1/2 Grade 3 Grade 4 Grade 5
HIPEC-related 9 10.2 9 — — —
Renal 6 6 — — —
Hematological 3 3 — — —
Infectious complications 42 47.7 31 7 1 3
Sepsis 2 — — — 2
Abdominal abscess 8 — 7 — 1
Central line-associated bloodstream infections 11 11 — — —
Wound infection 15 15 — — —
Pneumonia 6 5 — 1 —
Noninfectious complications 37 42.1 11 11 11 4
Acute postoperative pancreatitis 4 — 3 1 —
Pleural effusion 10 7 3 — —
Deep vein thrombosis 2 2 — — —
Transient ischemic attack 1 — — 1 —
Pulmonary embolism 2 — — — 2
Respiratory failure 4 2 — 2 —
Bowel perforation 4 — — 3 1
Anastomotic dehiscence 1 — — 1 —
Colostomy necrosis 1 — — 1 —
Urinary fistula 2 — 2 — —
Peritoneal bleeding 2 — 2 — —
Gastric bleeding 1 — 1 — —
Acute myocardial infarction 3 — — 2 1
Total 88 51 (57.9%) 18 (20.4%) 12 (13.6%) 7 (0.8%)
Table 3: Site and etiology of infectious complications.
Wound Abdominal drain CVL Bloodstream Vaginal Urine Total
Candida albicans 0 2 5 6 2 1 16
Escherichia coli 6 4 0 0 1 1 12
Klebsiella pneumonie 2 1 3 1 0 1 8
Enterobacter 2 4 0 0 0 0 6
Staphylococcus aureus 4 2 0 0 0 0 6
Staphylococcus coag neg 0 0 2 2 0 0 4
Enterococcus faecalis 2 2 0 0 0 0 4
Proteus mirabilis 0 0 0 0 2 0 2
Acinetobacter baumannii 0 0 1 1 0 0 2
Pseudomonas aeruginosa 2 0 0 0 0 0 2
Total 18 15 11 10 5 3 62
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uneventful recovery in 56% of the patients while 88 patients
experienced complications, 51 of them requiring no or only
medical treatment (grade 1/2). Grade 3 to 5 adverse events,
requiring interventional radiology, reoperation, or ICU
readmission, were reported in 18.5% of the patients. These
figures are similar to those reported for other major GI
operations [25, 31].
In the few previously published studies reporting infec-
tious complications, rates between 24 and 45% have been
observed, with an infection related mortality of 1-2%. Kusa-
mura et al. [6] reported 3.4% infectious complication rates
in 209 peritonectomies followed by HIPEC, and Sugarbaker
reported 42% infection rates in grade III adverse events and
5% rates in grade IV adverse events. In our series, the most
common grade 1-2 infectious complications were surgical
site infections and central line-associated bloodstream infec-
tions. Intra-abdominal fluid collections were the most fre-
quent major complication (grades 3-5). Despite bacterial
infections being more frequent, the Candida species were
the most isolated microbial agent. This data confirms a pre-
vious report from Capone et al. [2]. Regarding nutritional
status, it is crucial to emphasize that.
The importance of perioperative nutritional status in
major surgery is well-known [35]. BMI has been shown to
be a single clinical variable influencing surgical outcome
[36–38], and the serum albumin level is a well-known factor
predicting the risk of infectious complications and sepsis
[39, 40], and recent papers underlined the role of immune
stimulating diet or enteral nutrition prior to surgery [41].
In our study, we selected only patients within a normal
BMI range to avoid subgroups, underweight or obese, with
significant higher mortality and morbidity. Postoperative
serum albumin levels < 2 g/dl also correlated with higher
rates of infectious complications. Infectious complications
occurred more frequently in the mildly (B) or severely (C)
malnourished group when compared to the group of well-
nourished patients (A), highlighting the upmost importance
of nutritional status at the time of surgery and the need for
an effective perioperative nutritional support.
In patients undergoing cytoreductive surgery and HIPEC,
Uccella et al. found malnutrition as a factor predictive of a
higher rate of perioperative complications in patients with
advanced ovarian cancer undergoing upfront cytoreductive
surgery [42], and the results of the clinical trial “Perioperative
Table 4: Correlation between risk factors and infectious
complications (univariate analysis).
Variables
Patients (n = 200)
(%)
Infectious
complication
(n = 42) (%)
p
Age (years)
<61 82 (41) 19 (45) 0.06
>61 118 (59) 23 (55)
ASA score
<3 184 (92) 12 (28) 0.018∗
>3 16 (8) 30 (72)
SGA score
A 102 (51) 11 (26) 0.016∗
B/C 98 (49) 31 (74)
P. status (ECOG)
<2 107 (53) 15 (36) 0.03∗
>2 93 (47) 27 (64)
Cytoreduction
Primary 124 (62) 20 (48) 0.1
Secondary 76 (38) 22 (52)
PCI score
<15 62 (31) 16 (38) 0.05∗
>15 138 (69) 26 (62)
Ascites
Yes 92 (46) 23 (55) 0.06
No 108 (54) 19 (45)
Prev. chemotherapy
Yes 104 (52) 24 (57) 0.07
No 96 (48) 18 (43)
Intestinal
obstruction
Yes 42 (21) 20 (48) 0.1
No 158 (79) 22 (52)
Colorectal
resections
Yes 138 (69) 28 (67) 0.024∗
No 62 (31) 14 (33)
Length of surgical
procedure (min)
<423 159 (79.5) 17 (40) 0.059
>423 41 (20.5) 25 (60)
Number of surgical
procedures
<4 18 (9) 18 (43) 0.07
>4 182 (91) 24 (57)
Blood loss (ml)
<1400 93 (46.5) 13 (31) 0.04∗
>1400 107 (53.5) 29 (69)
ICU stay (hours)
<31 78 (39) 17 (40) 0.059
>31 122 (61) 25 (60)
Table 4: Continued.
Variables
Patients (n = 200)
(%)
Infectious
complication
(n = 42) (%)
p
HIPEC drugs
Cisplatin 132 (66) 20 (48) 0.1
Oxaliplatin 68 (34) 22 (52)
Post-op serum
albumin (g/dl)
<2 54 (27) 29 (69) 0.03∗
>2 146 (73) 13 (31)
∗Significant.
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Immunonutrition for Patients Undergoing Cytoreductive Sur-
gery (CRS) andHyperthermic Intraperitoneal Chemotherapy”
from the National Cancer Center of Singapore [43] investigat-
ing the impact of immune nutrition in reducing surgical site
infections and length of hospital stay should be available in
2019. Early start of enteral or parenteral nutrition and oral
feeding seems to be a protective factor towards postoperative
complications, and since early postoperative enteral nutrition
is not always possible inmost of these patients, it has been sug-
gested that early supplementary parenteral nutrition should be
given when resuming oral feeding is estimated greater than
three days [44]. Standard nutritional support (protein, vita-
mins, and minerals) and immunonutrition (arginine, nucleo-
tides, and omega 3 fatty acids) seem to both be good options
during the perioperative period in order to reduce the length
of stay and infectious complications in cancer patients [45, 46].
5. Conclusions
Malnourished patients (both mild and severely) are more
prone to postoperative infectious complications that account
for nearly 50% of all adverse events, and the Candida species
are the most frequent infective agent involved. Tumor load
(PCI score), ASA score, performance and nutritional status,
large bowel resection, and postoperative serum albumin
levels were the variables found to significantly influence the
rate of postoperative infectious complications in patients in
our group of patients with peritoneal metastases undergoing
CRS and HIPEC. Adequate perioperative nutritional support
including immunonutrition should be considered to reduce
postoperative infection rates in these patients.
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Table 5: Risk factors and infectious complications: multivariate
analysis (Cox regression model).
Variables DF
Sum of
squares
Mean
square
f ratio
Prob.
level
ASA score 3 2.110112 0.7033707 4.276 0.0072∗
<3
>3
Blood loss (ml) 1 0.6134862 0.6134862 3.729 0.0466∗
<1400
>1400
No. of surgical
procedures
1 0.1020328 0.1020328 0.620 0.4330
<4
>4
Performance status 3 0.1638669 5.462231 0.332 0.8022
<2
>2
Colonic resections 2 0.6366483 0.8336443 3.682 0.0487∗
Yes
No
SGA score 3 0.6246453 0.6366483 2.994 0.0422∗
A
B/C
Platinum-based
HIPEC
1 0.1644679 0.1664563 0.892 0.1422
Cisplatin
Oxaliplatin
Serum albumin
levels (g/dl)
1 0.6467919 0.7366533 2.124 0.0382∗
<2
>2
∗Significant.
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